News

BioPharma Dive1d

Insmed gains US approval of lung disease drug forecast to be blockbuster

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...

Bridgewater firm's stock jumps after FDA approves its new lung disease drug

BRIDGEWATER – Shares of Insmed, a pharmaceutical firm at the intersection of Route 202-206 and Allen Road, jumped 8% on the NASDAQ after the federal Food and Drug Administration approved the company's ...

FDA approves first drug for chronic lung condition bronchiectasis

For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration (FDA) has ...

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...
Fierce Pharma1d

Insmed’s Brinsupri scores landmark FDA nod in bronchiectasis, marking first approval of a DPP1 inhibitor

With a landmark U.S. approval  Tuesday, Insmed is making waves with a new class of drug that’s also the first to be green lit ...

US FDA approves Insmed's drug as first treatment for a chronic lung disease

The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday ...
BioSpace22h

Insmed Wins Approval for First Bronchiectasis Drug and DPP1 Blocker

Insmed's Brinsupri is the first DPP1 inhibitor approved by the FDA and the first treatment for bronchiectasis to reach the ...

US FDA approves Insmed's lung disease drug

The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday ...
STAT22h

Pharmalittle: We’re reading about FDA OK for a lung disease drug, pharma sales in China, and more

Insmed received FDA clearance for the first treatment for a chronic lung disease, opening the way to what could be a ...

Insmed CEO on what’s next for company after FDA greenlights lung disease drug

Will Lewis, Insmed CEO, joins 'Fast Money' to discuss the company's lung drug being greenlit by the FDA and what it means for ...
pharmaphorum1d

Insmed gets first FDA approval for bronchiectasis

Insmed has claimed the distinction of becoming the first company to get FDA approval for a treatment for chronic lung disease non-cystic fibrosis bronchiectasis (NFCB).